Table 3.
Distribution of clinicopathological characteristics according to tumour origin in 175 re-evaluated periampullary adenocarcinomas
| |
Duodenum |
Ampulla Intestinal type |
Ampulla Pancreatobiliary type |
Distal Bile Duct |
Pancreas |
All |
|---|---|---|---|---|---|---|
| n = 14 | n = 51 | n = 19 | n = 45 | n = 46 | n = 175 | |
| Standardized Procedure |
5 (36%) |
7 (14%) |
5 (26%) |
18 (40%) |
11 (24%) |
46 (26%) |
| Age at surgery, M (IQR) |
68 (62 – 74) |
67 (59 – 70) |
69 (62 – 75) |
64 (59 – 71) |
68 (62 – 72) |
67 (61 – 72) |
| Gender, Female |
6 (43%) |
29 (57%) |
9 (47%) |
21 (47%) |
21 (46%) |
86 (49%) |
| Tumour size, mm, M (IQR) |
40 (30 – 53) |
23 (15–30) |
30 (24 – 40) |
26 (22 – 35) |
30 (25 – 35) |
30 (21 – 35) |
| Larger than 20 mm |
13 (93%) |
27 (53%) |
18 (95%) |
37 (82%) |
39 (85%) |
134 (77%) |
| High grade |
7 (50%) |
26 (51%) |
9 (47%) |
31 (69%) |
28 (61%) |
101 (58%) |
| Lymph nodes, M (IQR) |
10 (6 – 13.5) |
9 (6 – 16) |
10 (5 – 17) |
12 (8 – 16.5) |
11.5 (6.75 – 16) |
11 (6 – 16) |
| 10 or more lymph nodes |
8 (57%) |
25 (49%) |
10 (53%) |
30 (67%) |
27 (59%) |
100 (57%) |
| Involved lymph nodes, M (IQR) |
0 (0 – 2) |
0 (0 – 2) |
2 (1 – 7) |
1 (0 – 4) |
2 (0 – 3) |
1 (0 – 3) |
| pN1 |
4 (29%) |
24 (47%) |
16 (84%) |
27 (60%) |
34 (74%) |
106 (61%) |
| pN2 |
2 (14%) |
|
|
|
|
|
| Perineural infiltration |
4 (29%) |
16 (31%) |
14 (74%) |
37 (82%) |
34 (74%) |
105 (60%) |
| Infiltration in lymph vessels |
2 (14%) |
34 (67%) |
15 (79%) |
33 (73%) |
27 (59%) |
111 (63%) |
| Infiltration in blood vessels |
0 (0.0%) |
5 (10%) |
8 (42%) |
14 (31%) |
15 (33%) |
42 (24%) |
| Infiltration in peripancreatic fat |
6 (43%) |
16 (31%) |
17 (89%) |
36 (80%) |
32 (70%) |
107 (61%) |
| T-stage (pTNM) |
|
|
|
|
|
|
| T1 |
0 |
5 (10%) |
0 |
1 (2%) |
2 (4%) |
|
| T2 |
1 (7%) |
11 (22%) |
0 |
2 (4%) |
10 (22%) |
|
| T3 |
6 (43%) |
19 (37%) |
2 (11%) |
42 (93%) |
34 (74%) |
|
| T4 |
7 (50%) |
16 (31%) |
17 (89%) |
0 |
0 |
|
| R1 |
3 (38%) |
10 (43%) |
14 (93%) |
32 (89%) |
35 (95%) |
94 (79%) |
| R0 |
5 (63%) |
13 (57%) |
1 (7%) |
4 (11%) |
2 (6%) |
25 (21%) |
| Rx,uncertain margin status (n) |
6 |
28 |
4 |
9 |
9 |
56 |
| Pancreatic transection margin |
1 (13%) |
1 (4%) |
1 (7%) |
5 (14%) |
10 (27%) |
18 (15%) |
| DBD transection margin |
0 |
0 |
0 |
2 (6%) |
1 (3%) |
3 (3%) |
| SMA-margin |
0 |
0 |
0 |
10 (28%) |
2 (5%) |
12 (10%) |
| Posterior margin |
2 (25%) |
6 (26%) |
6 (40%) |
17 (47%) |
11 (30%) |
42 (35%) |
| SMV-margin |
1 (13%) |
0 |
0 |
13 (36%) |
18 (49%) |
32 (27%) |
| Anterior margin |
1 (13%) |
1 (4%) |
2 (13%) |
5 (14%) |
5 (14%) |
14 (12%) |
| 5-year OS, M (IQR), months | n.r. (37 - n.r.) | 53 (26 - n.r.) | 26 (15–40) | 25 (16 - n.r.) | 25 (13–42) | 30 (17-n.r.) |
M, median. IQR, interquartile range. OS, overall survival. N.r., not reached.